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Effects of recombinant humant erythropoietin in normal humans
Abstract
This review describes some of the physiological effects of recombinant human erythropoietin (EPO) in
healthy humans. At the blood level EPO increases the arterial O2 content not only by increasing red
blood cell volume, but also by an equally important decrease in plasma volume. Well before that, EPO
causes a prompt decrease in plasma levels of renin and aldosterone. Renal clearance studies suggest that
EPO decreases renal proximal tubular reabsorption rate leading to activation of the tubuloglomerular
feedback mechanism and a fall in glomerular filtration rate. Thus, treatment with EPO may result in
suppression of endogenous EPO production through a decrease in intrarenal oxygen consumption. EPO
elevates the arterial blood pressure even in healthy subjects. The receptor for EPO is present in many
tissues. However, the functional effects of EPO in the skeletal muscle seem limited, and although it has
been speculated that non-erythropoietic effects of EPO (angiogenesis, shift in muscle fibre types,
cognitive effects) may be responsible for the increase in exercise performance, this has not been
confirmed. EPO induced haemodynamic effects call for careful monitoring during the administration
period. The metabolic, hormonal and renal effects of EPO does not seem to range beyond physiological
acceptable limits and are reversible. Taken together, EPO seems safe to use for experimental purposes in
healthy volunteers.
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Abstract 
This review describes some of the physiological effects of recombinant human 
erythropoietin (EPO) in healthy humans. At the blood level EPO increases the arterial O2 
content not only by increasing red blood cell volume, but also by an equally important 
decrease in plasma volume. Well before that, EPO causes a prompt decrease in plasma 
levels of renin and aldosterone. Renal clearance studies suggest that EPO decreases renal 
proximal tubular reabsorption rate leading to activation of the tubuloglomerular feedback 
mechanism and a fall in glomerular filtration rate. Thus, treatment with EPO may result 
in suppression of endogenous EPO production through a decrease in intrarenal oxygen 
consumption. EPO elevates the arterial blood pressure even in healthy subjects. The 
receptor for EPO is present in many tissues. However, the functional effects of EPO in 
the skeletal muscle seem limited, and although it has been speculated that non-
erythropoietic effects of EPO (angiogenesis, shift in muscle fibre types, cognitive effects) 
may be responsible for the increase in exercise performance, this has not been confirmed. 
EPO induced haemodynamic effects call for careful monitoring during the administration 
period. The metabolic, hormonal and renal effects of EPO does not seem to range beyond 
physiological acceptable limits and are reversible. Taken together, EPO seems safe to use 
for experimental purposes in healthy volunteers.  
 
Keywords: EPO, non erythropoietic, kidney, muscle, blood pressure, exercise, 
performance, plasma, blood, volume. 
) at Universitaetsspital, Bibliothek, CH-8091 ZUERICH on November 12, 2010jp.physoc.orgDownloaded from J Physiol (
 3
During the last decade many new and exciting functions have been attributed to 
erythropoietin (EPO), and many of these are related to non-erythropoietic effects 
(Jelkmann, 2007). This review outlines some of the most physiological relevant functions 
and mechanisms of EPO with an emphasis on studies conducted in healthy subjects. 
Several functions of EPO, i.e. inhibition of inflammation and apoptosis, anti-oxidant 
effects and stimulation of angiogenesis, may be of potential use in the treatment of 
pathological conditions but to address the clinical aspects is beyond the scope of the 
present review. Along with news of potentially beneficial effects attributed to EPO, also 
reports have been advanced, indicating that the mortality and morbidity rates are 
increased in some patient groups when treated with EPO (Phrommintikul et al., 2007; 
Ehrenreich et al., 2009; Pfeffer et al., 2009; Dicato & Plawny, 2010). Thus, the question 
arises whether it can be considered safe to conduct studies with EPO in normal subjects. 
  
 
The mechanisms by which EPO increases haematocrit and O2 transport capacity 
In healthy individuals with haematocrit values in the normal range, injections of around 
60 IU kg-1 one to three times per week in 4-14 weeks increase the haematocrit to just 
below 50 % (Table 1). The main mechanism for the increase in haematocrit was long 
thought to rely exclusively on augmentations in red cell mass, but it was demonstrated 
that EPO also decreases plasma volume (Lundby et al., 2007). In fact the relative 
contributions of an augmented red cell mass and a concomitant decrease in plasma 
volume to the increase in blood hemoglobin levels were almost equal over a 13 weeks 
period. This response may require a normal renal function and may not be observed in 
patients with kidney diseases. The plasma volume reducing effects of EPO was 
confirmed in other studies (Lundby et al., 2008a; Olsen et al., 2010). Noteworthy, the 
change in plasma volume preceded the increase in red blood cell volume. A preliminary 
study suggested that the newly formed erythrocytes undergo apoptosis once EPO 
stimulation is stopped, so that the EPO induced increase in red cell mass does not last the 
expected 120 days (Chang et al., 2009). In contrast, however, and based on direct 
measures of red cell mass following the termination of EPO stimulation, it would appear 
that haemoglobin concentration [Hb] is normalized rather rapidly due to a restoration in 
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plasma volume without an effect on red cell mass (Lundby et al., 2008a; Olsen et al., 
2010). This implies that although [Hb] and haematocrit are promptly returned toward 
baseline values after the EPO administration period, red cell O2 transport capacity may 
still remain elevated. How long red cell mass remains elevated following EPO treatment 
is at present unknown. 
  
 
The influence of EPO on blood pressure 
When treatment with EPO in anaemic states became widely appreciated it was 
recognized that long-term administration of EPO in patients with chronic kidney disease 
provokes arterial hypertension. The possible mechanisms for this effect which occurs 
independently of EPO’s haematopoietic effect have been recently reviewed (Krapf & 
Hulter, 2009). As shown in Table 1, however, in healthy subjects EPO injections 
sufficient to increase the haematocrit apparently do not increase the blood pressure. In 
these studies, blood pressure was usually not the main target investigated and was 
assessed by the use of sphygmomanometry. In contrast to these studies, the few studies 
assessing blood pressure by intraarterial pressure transducers reported a small increase in 
resting values (Lundby et al., 2007). During exercise, hemodilution following EPO 
treatment may revert the augmented blood pressure response (Lundby et al., 2008c). This 
suggests a significant role of enhanced blood viscosity in EPO induced hypertension 
during exercise. EPO induced hypertension may however also be unrelated to viscosity, 
as acute injections of high EPO doses (30,000 IU/day for three days) increases both 
resting arterial blood pressure and the blood pressure response to exercise in normal 
subjects (Rasmussen et al., 2010). EPO treatment with prolonged low-dose 
administration or high doses for three days both induced an increase in total peripheral 
resistance, and, as assessed by transcranial Doppler measurements and cerebral arterio-
venous differences in oxygen content, this vasoconstriction also included the 
cerebrovascular circulation. The mechanisms remains unclear, but may involve EPO 
induced release of endothelin (Bode-Böger et al., 1996) and inhibition of eNOS mediated 
production of NO (Wang & Vaziri, 1999; Scalera et al., 2005). EPO has also been shown 
to possess direct vasoconstrictive effects in isolated renal resistance vessels (Heidenreich 
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et al., 1991) and human placental arteries in vitro (Resch et al., 2003). Thus, in normal 
subjects both long-term administration of low doses of EPO and short-term bouts of high-
dose EPO may produce arterial hypertension and intracerebral vasoconstriction.  
 
Metabolism: a functional regulating role of EPO? 
In haemodialysis patients it was demonstrated that EPO treatment over a one year period 
lowered BMI from 22.7 to 22.1 if food intake was not increased (Allegra et al., 1997). 
Because resting metabolic rate is not altered after prolonged EPO treatment in healthy 
individuals (Lundby et al., 2008c), and since leptin, which is secreted by the adipose 
tissue in proportion to the fat stores (Rosenbaum & Leibel, 1999), is decreased after 3 to 
6 months of EPO treatment (Kokot et al., 1998) it could be that EPO induced a reduction 
in BMI by a fat tissue reducing effect. In this regard, supra-physiological EPO doses may 
protect against obesity in mice if on a high fat diet (Hojman et al., 2009). Furthermore, 
trials in diabetic, chronic renal disease patients have shown that EPO improves several 
metabolic parameters including fasting glucose level and insulin sensitivity as measured 
by euglycaemic hyperinsulinaemic clamp and intravenous glucose tolerance test 
(Borissova et al., 1993; Allegra et al., 1996). These findings are however not supported 
by experiments where very high EPO doses (400 IU/kg) were applied in combination 
with insulin clamp but did not show effects on glucose or fat metabolism at the skeletal 
muscle level in healthy humans (Christensen et al., 2010). It was concluded that EPO 
injections were not accompanied by distinct alteration in the pattern of substrate 
metabolism or insulin sensitivity. None of the studies listed in Table 1 have confirmed 
the early reports of EPO induced changes in body composition, and taken together, EPO 
in normal subjects does not seem to have major metabolic effects. 
 
Skeletal muscle 
Recently the receptor for EPO was reported in biopsies obtained from human skeletal 
muscle (Lundby et al., 2008b), (Rundqvist et al., 2009). Whether this also implies a 
functional role or not has been questioned (Sinclair et al., 2010). Nevertheless, it seems 
that EPO injections in healthy volunteers may affect the human skeletal muscle both 
direct and indirectly. With acute injections of 15.000 IU the mRNA levels of VEGF, 
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HIF-1α, IGF, ferroportin, MyoD, and myogen remained unchanged in biopsies obtained 
2, 4, 6, and 10 hours after the EPO injections, whereas minor inductions were observed in 
myoglobin, epo-r, transferin receptor, and MRF4 (Lundby et al., 2008b). Although this 
implies that EPO has at least some direct effects on the skeletal muscle, the physiological 
consequence hereof seems very limited because long term EPO treatment did not have 
any effect on the absolute number of capillaries, fiber type distribution, cross sectional 
area of the fibers (Lundby et al., 2008b), or in the majority of proteins involved in acid-
base balance, except for a decrease in the Na+,K+-pump subunit α2 (Juel et al., 2007). In 
the later study also no difference in muscle mass (or body composition) were reported 
following DEXA scans (Lundby et al., 2008b). EPO may however indirectly affect the 
human skeletal muscle. It has been hypothesized that EPO injections would cause 
skeletal muscle iron stores to decrease in order to make iron available for red cell 
formation (Robach et al., 2007). However, on the contrary, following injections with 
EPO skeletal muscle accumulates iron despite systemic iron deficiency secondary to EPO 
induced erythropoiesis and hepcidin promoting suppression of iron store mobilization 
(Robach et al., 2009). The exact mechanism for this remains at present unknown.    
 
The renin-angiotensin-aldosterone system and renal function 
Production of endogenous EPO is regulated by the renin-angiotensin system (Dunn et al., 
2007). When normal human subjects are given angiotensin II the plasma levels of EPO 
increases (Freudenthaler et al., 2000; Gossmann et al., 2001), and, conversely, inhibition 
of angiotensin converting enzyme decreases plasma EPO (Pratt et al., 1992). The changes 
in EPO synthesis are probably mediated through an angiotensin II receptor-1 dependent 
pathway (Gossmann et al., 2001). We have shown the presence of a contra-productive 
pathway by which treatment with EPO promptly, and before any changes in haematocrit, 
blood volumes and blood pressure can be detected, down-regulates circulating levels of 
renin and aldosterone (Lundby et al., 2007; Olsen et al., 2010).  
Concomitant clearance studies revealed that the EPO induced decrease in renin and 
aldosterone was associated with a fall in glomerular filtration rate (GFR). Furthermore, 
lithium clearance, used as an index of proximal tubular outflow, increased indicating a 10 
– 16 % decrease in proximal tubular reabsorption of sodium and water (Olsen et al., 
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2010). Changes in end-proximal delivery of tubular fluid to the macula densa produce 
inverse changes in renin release (Briggs et al., 1990) and thus the suppression of plasma 
renin levels may be secondary to direct effects of EPO on proximal tubular reabsorption. 
In addition, a decrease in proximal tubular reabsorption activates the tubuloglomerular 
feedback mechanism causing a parallel decrease in GFR (Holstein-Rathlou, 1991). The 
molecular mechanisms for EPO’s effect on the proximal tubule remain unknown but may 
involve inhanced release of renal endothelin-1 (Bode-Böger et al., 1996) which in low 
doses attenuates sodium reabsorption in the proximal tubule (Clavell et al., 1995). 
Tubular reabsorption of sodium is the main oxygen consuming process in the kidney and 
around 70 % of the filtered load is reabsorbed in the proximal tubule. By inhibiting 
proximal tubular reabsorption, which in turn results in rapid declines in GFR and 
renin/aldosterone levels, EPO directly reduces the major oxygen consuming factor in the 
kidney, reduces the filtered load, and decreases angiotensin II and aldosterone dependent 
reabsorption in more distal nephron segments. The expected result will be an increase of 
the oxygen tension in the environment of renal EPO producing cells, in this way initiating 
an appropriate signal for down-regulation of endogenous EPO synthesis when circulating 
levels of recombinant EPO are high (Figure 1). In support of such a feedback system, 
evidence exists to indicate that prolonged administration of recombinant EPO results in a 
suppression of urinary excretion of endogenous EPO (Lasne et al., 2002), and also the 
renal effects of recombinant EPO fits well in the hypothesis that the kidney operates as a 
‘critmeter’ to regulate the EPO synthesis and body haematocrit through the metabolic 
signal of renal tissue oxygen pressure (Donnelly, 2003).  
 
The reduction in plasma volume induced by EPO may be caused by natriuresis secondary 
to the hyporeninemic hypoaldosteronism (Lundby et al 2007, Krapf & Hulter 2009). The 
renal sodium loss necessary to account for the associated decrease in plasma volume is 
small and perhaps the net effect of EPO is to cause a negative sodium balance during the 
treatment period.  
 
Exercise capacity 
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Exercise performance is the result of multiple factors. Most studies investigating the 
effects of EPO on performance have evaluated maximal oxygen uptake (VO2max). When 
haematocrit is increased from base values to around 50 % VO2max is increased by 8-12 
% (Audran et al., 1999; Birkeland et al., 2000; Russell et al., 2002; Thomsen et al., 2007; 
Lundby et al., 2008a; Lundby et al., 2008c; Robach et al., 2008). The performance 
enhancing effects of EPO on VO2max at different altitudes has been investigated, and it 
was demonstrated that EPO provided the greatest advantage at medium altitudes (1500-
2500 m) (Lundby & Damsgaard, 2006; Robach et al., 2008). One study has assessed the 
performance gains at submaximal exercise intensities, and demonstrated improvements of 
more than 50 % in a time to exhaustion test (Thomsen et al., 2007). Exercise performance 
could be increased by other factors than those attributed to changes in red blood cell 
volume. In subjects hemodiluted isovolumically (Lundby et al., 2008c), i.e. restoring 
blood parameters to pre EPO treatment values following 13 weeks of EPO treatment, 
however, VO2max was similar to the values obtained prior to any injections. Since in this 
study the EPO dosages was likely too small to cross the blood brain barrier, and since 
EPO induces the perception of superior physical fitness (Ninot et al., 2006), Rasmussen 
and co-workers (Rasmussen et al., 2010) injected 30.000 IU in three consecutive days to 
test whether EPO crossing the brain blood barrier, and hence potentially interact with the 
CNS, could increase submaximal exercise performance. Analysis of spinal fluid revealed 
a massive increase in EPO following the injections, and hence proved that EPO had in 
fact crossed the blood brain barrier. Also in this study however, no changes in exercise 
performance were noted, and surprisingly the rate of perceived exertion during the 
exercise become worse. Also in this regard, it was elegantly demonstrated that the O2-
kinetics during the onset of exercise is not altered by EPO (Wilkerson et al., 2005), 
something that had been proposed a few years earlier (Connes et al., 2003). Thus, there is 
no evidence indicating that EPO should increase exercise performance by other 
mechanisms than by increasing oxygen transport capacity. One could speculate that an 
increase in nHb may positively influence repeated sprint performance because of 
increased buffer capacity, but this remains unexplored. 
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Cognitive function 
Although EPO did not reduce the central fatigue during exercise (Rasmussen et al., 
2010), evidence now exist to suggest that high doses modulates neural processing and 
may improve cognitive function 3 and 7 days after the administration of EPO 
(Miskowiak et al 2008a, 2008b). 40.000 IE of intravenously administered EPO lead to 
better performance in healthy subjects in a test of verbal fluency 7 days after injection of 
EPO (Miskowiak et al 2008a). Concomitant use of functional magnetic resonance 
imaging demonstrated that EPO has enduring effect on neurotrophic signaling in neural 
networks often affected in neuropsychiatric diseases (Miskowiak et al 2008a, 2008b). 
Also a beneficial effect of 12 weekly injections of 40.000 IU of EPO on cognitive 
function has been reported in patients with schizophrenia (Ehrenreich et al 2007). 
 
Is it safe to conduct studies with EPO in healthy volunteers? 
EPO has emerged as a pleiotropic substance with multiple targets of action. The question 
arises whether the newly discovered effects of EPO hamper its use in physiological 
research studies beyond the risk associated with known haematopoitic effects. Of greatest 
concern is the fact that EPO may increase arterial blood pressure even in healthy subjects. 
Noteworthy, also short-term administration of high EPO doses may cause peripheral and 
intracerebral vasoconstriction. Although the effect is small it may call for careful 
monitoring of the blood pressure during the administration period. The metabolic, 
hormonal and renal effects of EPO are small and does not seem to range beyond 
physiological acceptable limits. Furthermore, the effects observed thus far have been 
fully reversible. Taken together, the new evidence may call for more information to 
subjects participating in EPO trials but does not push the stop button.  
 
References 
Allegra V, Martimbianco L & Vasile A. (1997). Lipid and apolipoprotein patterns during 
erythropoietin therapy: roles of erythropoietin, route of administration, and diet. 
Nephrol Dial Transplant 12, 924-932. 
 
Allegra V, Mengozzi G, Martimbianco L & Vasile A. (1996). Early and late effects of 
erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J 
Nephrol 16, 304-308. 
) at Universitaetsspital, Bibliothek, CH-8091 ZUERICH on November 12, 2010jp.physoc.orgDownloaded from J Physiol (
 10
 
Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart M-T, Marion B & 
Bressolle F. (1999). Effects of erythropoietin administration in training athletes 
and possible indirect detection in doping control. . Med Sci Sports Exerc 31, 639-
645. 
 
Berglund B & Ekblom B. (1991). Effect of recombinant human erythropoietin treatment 
on blood pressure and some haematological parameters in healthy men. J Intern 
Med 229, 125-130. 
 
Birkeland KI, Stray-Gundersen JIM, Hemmersbach P, Hallen J, Haug E & Bahr R. 
(2000). Effect of rhEPO administration on serum levels of sTfR and cycling 
performance. Med Sci Sports Exerc 32, 1238-1243. 
 
Bode-Böger SM, Böger RH, Kuhn M, Radermacher J & Frölich JC. (1996). Recombinant 
human erythropoietin enhances vasoconstrictor tone via endothelin-1 and 
constrictor prostanoids. Kidney Int 50, 1255-1261. 
 
Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T & Kirilov G. 
(1993). Effect of erythropoietin on the metabolic state and peripheral insulin 
sensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant 8, 93-. 
 
Briggs J, Skott P & Schnermann J. (1990). Cellular mechanisms within the 
juxtaglomerular apparatus. Am J Hypertension 3, 76-80. 
 
Chang C, Chen Y, Modi K, Awar O, Alfrey C & Rice L. (2009). Changes of red blood 
cell surface markers in a blood doping model of neocytolysis. J Investig Med 57, 
650-654. 
 
Christensen B, Vendelbo MH, Krusenstjerna-Hafstrom T, Madsen M, Pedersen SB, 
Jessen N, Moller N & Jorgensen JOL. (2010). Erythropoietin administration 
acutely stimulates resting energy expenditure in healthy young men. Journal of 
Clinical Endocrinology and Metabolism, in revision. 
 
Clavell AL, Stingo AJ, Margulies KB, Brandt RR & Burnett JC, Jr. (1995). Role of 
endothelin receptor subtypes in the in vivo regulation of renal function. Am J 
Physiol Renal Physiol 268, F455-460. 
 
Connes P, Perrey S, Varray A, Préfaut C & Caillaud C. (2003). Faster oxygen uptake 
kinetics at the onset of submaximal cycling exercise following 4 weeks 
recombinant human erythropoietin (r-HuEPO) treatment. Pflügers Arch 447, 231-
238. 
 
Dicato M & Plawny L. (2010). Erythropoietin in cancer patients: pros and cons. . Curr 
Opin Oncol 22, 307-311. 
 
) at Universitaetsspital, Bibliothek, CH-8091 ZUERICH on November 12, 2010jp.physoc.orgDownloaded from J Physiol (
 11
Donnelly S. (2003). Why is erythropoietin made in the kidney? The kidney functions as a 
'critmeter' to regulate the hematocrit. Adv Exp Med Biol 543, 73-87. 
 
Dunn A, Lo V & Donnelly S. (2007). The role of the kidney in blood volume regulation: 
the kidney as a regulator of the hematocrit. Am J Med Sci 334, 65-71. 
 
Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, 
Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jahnig P, Herrmann M, Knauth 
M, Bahr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, 
Dengler R, Kastrup A, Bartels C & for the EPO Stroke Trial Group. (2009). 
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. 
Stroke 40, e647-656. 
 
Freudenthaler SM, Lucht I, Schenk T, Brink M & Gleiter CH. (2000). Dose-dependent 
effect of angiotensin II on human erythropoietin production. Pflügers Arch 439, 
838-844. 
 
Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Geiger H & 
Scheuermann E-H. (2001). Angiotensin II infusion increases plasma 
erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. 
Kidney Int 60, 83-86. 
 
Heidenreich S, Rahn K & Zidek W. (1991). Direct effects of recombinant human 
erythropoietin on renal resistance vessels. Kidney Int 39, 259-265. 
 
Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK & Gehl J. (2009). 
Erythropoietin Over-Expression Protects against Diet-Induced Obesity in Mice 
through Increased Fat Oxidation in Muscles. PLoS ONE 4, e5894. 
 
Holstein-Rathlou NH. (1991). A closed-loop analysis of the tubuloglomerular feedback 
mechanism. Am J Physiol Renal Physiol 261, F880-889. 
 
Jelkmann W. (2007). Erythropoietin after a century of research: younger than ever. Eur J 
Haematol 78, 183-205. 
 
Juel C, Thomsen J, Rentsch R & Lundby C. (2007). Effects of prolonged recombinant 
human erythropoietin administration on muscle membrane transport systems and 
metabolic marker enzymes. Eur J Appl Physiol 102, 41-44. 
 
Kokot F, Wiecek A, Mesjasz J, Adamczak M & Spiechowicz U. (1998). Influence of 
long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin 
and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol 
Dial Transplant 13, 1200-1205. 
 
Krapf R & Hulter HN. (2009). Arterial Hypertension Induced by Erythropoietin and 
Erythropoiesis-Stimulating Agents (ESA). Clin J Am Soc Nephrol 4, 470-480. 
) at Universitaetsspital, Bibliothek, CH-8091 ZUERICH on November 12, 2010jp.physoc.orgDownloaded from J Physiol (
 12
 
Lasne F, Martin L, Crepin N & de Ceaurriz J. (2002). Detection of isoelectric profiles of 
erythropoietin in urine: differentiation of natural and administered recombinant 
hormones. Anal Biochem 311, 119-126. 
 
Lundby C, Achman-Andersen NJ, Thomsen JJ, Norgaard AM & Robach P. (2008a). 
Testing for recombinant human erythropoietin in urine: problems associated with 
current anti-doping testing. J Appl Physiol 105, 417-419. 
 
Lundby C & Damsgaard R. (2006). Exercise performance in hypoxia after novel 
erythropoiesis stimulating protein treatment. Scand J Med Sci Sports 16, 35-40. 
 
Lundby C, Hellsten Y, Jensen MBF, Munch AS & Pilegaard H. (2008b). Erythropoietin 
receptor in human skeletal muscle and the effects of acute and long-term 
injections with recombinant human erythropoietin on the skeletal muscle. J Appl 
Physiol 104, 1154-1160. 
 
Lundby C, Robach P, Boushel R, Thomsen JJ, Rasmussen P, Koskolou M & Calbet JAL. 
(2008c). Does recombinant human Epo increase exercise capacity by means other 
than augmenting oxygen transport? J Appl Physiol 105, 581-587. 
 
Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JAL & Robach P. 
(2007). Erythropoietin treatment elevates haemoglobin concentration by 
increasing red cell volume and depressing plasma volume. J Physiol 578, 309-
314. 
 
Ninot G, Connes P & Caillaud C. (2006). Effects of recombinant human erythropoietin 
injections on physical self in endurance athletes. Journal of Sports Sciences 24, 
383 - 391. 
 
Olsen NV, Aachmann-Andersen NJ, Oturai P, Andersen TM, Rasmussen AB, Hulston C, 
Holstein-Rathlou N-H, Robach P & Lundby C. (2010). Recombinant human 
erythropoietin in humans down-regulates proximal renal tubular reabsorption and 
causes a fall in glomerular filtration rate. The Journal of Physiology. 
 
Parisotto R, Gore C, Emslie K, Ashenden M, Brugnara C, Howe C, Martin D, Trout G & 
Hahn A. (2000). A novel method utilising markers of altered erythropoiesis for 
the detection of recombinant human erythropoietin abuse in athletes. 
Haematologica 85, 564-572. 
 
Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, Feyzi 
JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray 
JJV, Parfrey P, Parving H-H, Remuzzi G, Singh AK, Solomon SD, Toto R & the 
TREAT Investigators. (2009). A Trial of Darbepoetin Alfa in Type 2 Diabetes 
and Chronic Kidney Disease. N Engl J Med 361, 2019-2032. 
 
) at Universitaetsspital, Bibliothek, CH-8091 ZUERICH on November 12, 2010jp.physoc.orgDownloaded from J Physiol (
 13
Phrommintikul A, Haas SJ, Elsik M & Krum H. (2007). Mortality and target 
haemoglobin concentrations in anaemic patients with chronic kidney disease 
treated with erythropoietin: a meta-analysis. The Lancet 369, 381-388. 
 
Pratt MC, Lewis-Barned NJ, Walker RJ, Bailey RR, Shand Bl & Livesey J. (1992). 
Effect of angiotensin converting enzyme inhibitors on erythropoietin 
concentrations in healthy volunteers. Br J Clin Pharmacol 34, 363-365. 
 
Rasmussen P, Foged EM, Krogh-Madsen R, Nielsen J, Nielsen TR, Olsen NV, Petersen 
NC, Sorensen TA, Secher NH & Lundby C. (2010). Effects of erythropoietin 
administration on cerebral metabolism and exercise capacity in men. J Appl 
Physiol 109, 476-483. 
 
Resch BE, Gaspar R, Sonkodi S, Ds, Falkay G & Dsc. (2003). Vasoactive effects of 
erythropoietin on human placental blood vessels in vitro. American Journal of 
Obstetrics and Gynecology 188, 993-996. 
 
Robach P, Cairo G, Gelfi C, Bernuzzi F, Pilegaard H, Vigano A, Santambrogio P, 
Cerretelli P, Calbet JAL, Moutereau S & Lundby C. (2007). Strong iron demand 
during hypoxia-induced erythropoiesis is associated with down-regulation of iron-
related proteins and myoglobin in human skeletal muscle. Blood 109, 4724-4731. 
 
Robach P, Calbet JAL, Thomsen JJ, Boushel R, Mollard P, Rasmussen P & Lundby C. 
(2008). The Ergogenic Effect of Recombinant Human Erythropoietin on 
VO2max Depends on the Severity of Arterial Hypoxemia. PLoS ONE 3, e2996. 
 
Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen JJ, 
Norgaard AM, Alberghini A, Campostrini N, Castagna A, Vigano A, 
Santambrogio P, Kempf T, Wollert KC, Moutereau S, Lundby C & Cairo G. 
(2009). Alterations of systemic and muscle iron metabolism in human subjects 
treated with low-dose recombinant erythropoietin. Blood 113, 6707-6715. 
 
Rosenbaum M & Leibel RL. (1999). The Role of Leptin in Human Physiology. N Engl J 
Med 341, 913-915. 
 
Rundqvist H, Rullman E, Sundberg CJ, Fischer H, Eisleitner K, Stahlberg M, Sundblad 
P, Jansson E & Gustafsson T. (2009). Activation of the erythropoietin receptor in 
human skeletal muscle. Eur J Endocrinol 161, 427-434. 
 
Russell G, Gore C, Ashenden M, Parisotto R & Hahn A. (2002). Effects of prolonged low 
doses of recombinant human erythropoietin during submaximal and maximal 
exercise. Eur J Appl Physiol 86, 442-449. 
 
Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M & Bode-Boger SM. 
(2005). Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial 
) at Universitaetsspital, Bibliothek, CH-8091 ZUERICH on November 12, 2010jp.physoc.orgDownloaded from J Physiol (
 14
Cells: Role of Dimethylarginine Dimethylaminohydrolase. J Am Soc Nephrol 16, 
892-898. 
 
Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, 
Elliott S & Begley CG. (2010). Functional erythropoietin receptor is undetectable 
in endothelial, cardiac, neuronal, and renal cells. Blood 115, 4264-4272. 
 
Thomsen J, Rentsch R, Robach P, Calbet J, Boushel R, Rasmussen P, Juel C & Lundby 
C. (2007). Prolonged administration of recombinant human erythropoietin 
increases submaximal performance more than maximal aerobic capacity. Eur J 
Appl Physiol 101, 481-486. 
 
Wang XQ & Vaziri ND. (1999). Erythropoietin Depresses Nitric Oxide Synthase 
Expression by Human Endothelial Cells. Hypertension 33, 894-899. 
 
Wilkerson DP, Rittweger J, Berger NJA, Naish PF & Jones AM. (2005). Influence of 
recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics 
during exercise in humans. J Physiol 568, 639-652. 
 
 
  
 
 
 
 
 
 
) at Universitaetsspital, Bibliothek, CH-8091 ZUERICH on November 12, 2010jp.physoc.orgDownloaded from J Physiol (
 15
Table 1. Effects of EPO injections in healthy subjects on haematocrit (htc), haemoglobin concentration ([Hb]), body weight and 
arterial blood pressure. 
Injection 
period 1 
Injection 
period 2 
Iron 
supplementation 
Pre htc (%) / 
Hb (g.dl-1) 
Post htc (%) / 
Hb (g.dl-1) 
Changes in 
body mass 
Blood 
pressure 
Reference 
3/week for 5 
weeks @ 50 
IU.kg-1 
3/week for 3 
weeks @ 20 
IU.kg-1 
Oral supplement 41.9 / 14.2 48.6 / 16.8 No change  (Russell et al., 
2002) 
3/week for 5 
weeks @ 50 
IU.kg-1 
3/week for 3 
weeks @ 20 
IU.kg-1 
Intravenous 
infusion  
43.6 / 15.0 49.1 / 17.1 No change  (Russell et al., 
2002) 
10/3 weeks @ 
60 IU.kg-1 
1/week for 9 
weeks @ 
60IU.kg-1 
Oral supplement 42.0 / 14.2 
g.dl-1 
49.0 / 17.1 
g.dl-1 
No change + 9 mmHg (Lundby et al., 
2007) 
Daily for 26 
days @ 50 
IU.kg-1 
 Oral supplement 44.4 % / 15.1 
g.dl-1 
 47.9% / 15.9 
g.dl-1* 
No change  (Audran et al., 
1999) 
3/week for 4 
weeks @ 60-
77 IU.kg-1 
 Oral supplement 42.7 %  50.8% * No change  (Birkeland et 
al., 2000) 
3/week for 6 
weeks @ 20-
40 IU.kg-1 
  44.5% 49.7% No change No change§ (Berglund & 
Ekblom, 1991) 
1/week for 4 
weeks @ 150 
IU.kg-1 
 No supplement 43% / 15.8 
g.dl-1 
49% / 16.9 
g.dl-1 
No change No change (Wilkerson et 
al., 2005) 
Every second 
day/2 weeks 
@ 65 IU.kg-1 
1/week for 2 
weeks @ 65 
IU.kg-1 
No supplement 43.9% 46.8% No change  + 4 mmHg (Lundby et al., 
2008a) 
3/weekly for 4 
weeks @ 50 
 Oral supplement 44.4% / 14.6 
g.dl-1 
48.1% / 16.0 
g.dl-1 
No change  (Connes et al., 
2003) 
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IU.kg-1 
12/26 days @ 
50 IU.kg-1 
 Intramuscular 
injections 
14.8 g.dl-1 15.9 g.dl-1 No change  (Parisotto et al., 
2000) 
12/26 days @ 
50 IU.kg-1 
 Oral 
supplementation 
15.0 g.dl-1 16.6 g.dl-1 No change  (Parisotto et al., 
2000) 
*Two subjects were stopped because htc increased to over 50%, § Blood pressure was increased during submaximal exercise.  
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Figure legend 
Figure 1.  How high levels of circulating recombinant EPO by intrinsic renal effects may result in suppression of endogenous EPO 
synthesis secondary to a decrease in intrarenal oxygen consymption: 1) EPO decreases reabsorption of sodium and fluid in the 
proximal tubule, thereby directly reducing the major oxygen consuming process in the kidney; 2) increase in end-proximal tubular 
delivery to the Macula Densa decreases renin release and subsequent angiotensin II and aldosterone dependent reabsorption in more 
distal nephron segments; 3) decreased proximal tubular reabsoprtion activates the tubuloglomerular feedback mechanism producing a 
fall in GFR and reduction of the filtered load; 4) the resulting increase in renal oxygen partial pressure in the environment of  
interstitial fibroblast-like cells down-regulates the hypoxia-inducible factor-2 dependent production of endogenous EPO. 
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